Solid Biosciences insider plans sale of 80,258 shares

Solid Biosciences insider Form 144 filing shows a planned sale of 80,258 shares of common stock through E*TRADE Financial on or after 02/02/2026, with an aggregate market value of $516,612.72.

Accepted by SEC EDGAR 02/02/2026 - 08:03 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Solid Biosciences insider Form 144 filing shows a planned sale of 80,258 shares of common stock through E*TRADE Financial on or after 02/02/2026, with an aggregate market value of $516,612.72. The filing notes 82,561,235 shares outstanding and a prior sale of 10,808 shares for $55,228.88 in the past three months.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the SLDB Form 144 filing disclose?

The Form 144 filing discloses a planned sale of 80,258 shares of Solid Biosciences common stock. These shares have an aggregate market value of $516,612.72 and are expected to be sold through E*TRADE Financial Corporation on or after February 2, 2026.

How many SLDB shares are planned to be sold in this Form 144?

The filing indicates a planned sale of 80,258 shares of Solid Biosciences common stock. These shares were acquired on February 2, 2026 via settlement of performance shares as compensation from the issuer, and are listed for sale on the Nasdaq through E*TRADE Financial.

What prior SLDB stock sales are reported in the last three months?

The document reports that Cumbo Alexander sold 10,808 shares of Solid Biosciences common stock on December 3, 2025. Those shares generated gross proceeds of $55,228.88, and this transaction is disclosed alongside the newly planned sale under Rule 144 requirements.

What is the reported market value of the SLDB shares to be sold?

The planned 80,258-share sale of Solid Biosciences common stock has an aggregate market value of $516,612.72. This value reflects the market pricing used in the Form 144 notice for the proposed Nasdaq transaction through E*TRADE Financial Corporation.

How many Solid Biosciences shares are outstanding in this filing?

The Form 144 notes that Solid Biosciences has 82,561,235 shares of common stock outstanding. This figure provides context for the planned 80,258-share sale disclosed in the filing, which is to be executed on the Nasdaq through E*TRADE Financial Corporation.

How were the SLDB shares being sold in this Form 144 acquired?

The 80,258 Solid Biosciences shares were acquired on February 2, 2026 as a settlement of performance shares from the issuer. The filing classifies the nature of payment as compensation rather than a cash purchase, which is typical for equity-based awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001685994
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Solid Biosciences Inc.
SEC File Number	001-38360
Address of Issuer	500 Rutherford Avenue Charlestown MASSACHUSETTS 02129
Phone	(617)-337-4680
Name of Person for Whose Account the Securities are To Be Sold	Cumbo Alexander
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE 500 RUTHERFORD AVENUE, THIRD FLOOR ALPHARETTA GA 30005	80258	516612.72	82561235	02/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/02/2026	Settlement of performance shares	Issuer			80258	02/02/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Cumbo Alexander 500 Rutherford Avenue CHARLESTOWN MA 02129	Common Stock	12/03/2025	10808	55228.88

144: Remarks and Signature

Remarks	The sale reported on this Form 144 was made to cover witholding taxes following the vesting of previously granted performance stock units pursuant to a durable sale instruction letter adopted by Mr. Cumbo on August 18, 2024 effecting the sell-cover-election. The sale does not represent a discretionary trade by Mr. Cumbo.
Date of Notice	02/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/18/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kimberly Cornwell as attorney-in-fact for Alexander Cumbo
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)